aTyr Pharma, Inc. ATYR
Regular-session close
After hours · Nov 19, 4:12 PM ET
- YTD
- -88.22%
- 1 year
- -86.33%
5D -2.66 (-41.30%)
- Market cap
- 9.41M
- Revenue (ttm)
- 235.00K
- EPS (ttm)
- -21.64
- Shares out
- 83.94M
- Forward P/E
- -4.33
- YTD return
- -88.22%
- 1-year return
- -86.33%
- 50-day average
- 3.17
- 200-day average
- 2.14
- Volume
- 80.56K
- Avg volume
- 113.21K
- Open
- 4.10
- Previous close
- 4.08
- Day's range
- 3.69 – 4.21
- 52-week range
- 3.69 – 44.40
- Beta
- 1.10
- Analysts
- Buy
- Price target
- 21.29 (+476.8%)
Key statistics
- Enterprise value
- 228.60M
- Price / sales
- 1221.63
- Price / book
- 3.97
- Free cash flow
- -41.67M
- Total cash
- 65.99M
- Total debt
- 13.57M
- Return on equity
- -78.14%
- Short % of float
- 3.41%
Fundamental scorecard
5 of 25 checks passed on ATYR’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.22 | -0.23 | -0.01 | -4.55% |
| Aug 13, 2024 | Jun 1, 2024 | -0.22 | -0.23 | -0.01 | -4.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2024 | Wells Fargo | init | — | Overweight |
| Sep 5, 2024 | Jefferies | init | — | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- atyrpharma.com
News
aTyr Pharma Files ~$80M At-The-Market Offering To Sell Common Stock Through Jefferies
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $6
Wells Fargo Maintains Equal-Weight on aTyr Pharma, Raises Price Target to $4
aTyr Pharma Q3 EPS $(7.43) Misses $(4.00) Estimate
12 Health Care Stocks Moving In Wednesday's Intraday Session aTyr Pharma Announces 1-For-40 Reverse Stock Split, Effective Oct. 28
aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor
Your note
Sign in to keep a note on ATYR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROADFOOT JILL MARIE | Chief Financial Officer | Sale | Feb 5, 2024 | 20,821 |
| CLARKE JOHN K. | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 19,797 |
| COUGHLIN TIMOTHY P | Director | Purchase | May 29, 2024 | 0 |
| DENYES NANCY | General Counsel | Purchase | Jun 4, 2024 | 22,267 |
| GROSS JANE A | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 6,000 |
| LUCAS SVETLANA | Director | Conversion of Exercise of derivative security | Apr 25, 2023 | 6,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes, Inc. | 17.47% | 14,666,600 | 50.16M | Sep 29, 2024 |
| FMR, LLC | 13.54% | 11,369,429 | 38.88M | Sep 29, 2024 |
| Vanguard Group Inc | 3.56% | 2,987,578 | 10.22M | Sep 29, 2024 |
| Tikvah Management LLC | 2.93% | 2,460,833 | 8.42M | Sep 29, 2024 |
| Logos Global Management LP | 2.38% | 2,000,000 | 6.84M | Sep 29, 2024 |
| Checkpoint Capital L.P. | 2.07% | 1,736,477 | 5.94M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 9.35% | 7,850,000 | 26.85M | Jul 30, 2024 |
| Federated Hermes Kaufmann Small Cap Fund | 7.89% | 6,620,000 | 22.64M | Jul 30, 2024 |
| Fidelity Growth Company Fund | 3.44% | 2,887,967 | 9.88M | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 3.01% | 2,524,394 | 8.63M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.46% | 2,065,835 | 7.07M | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 1.25% | 1,052,049 | 3.60M | Oct 30, 2024 |
